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Developing a computational workflow for eQTL analysis on the X chromo-
some
Despite advances in sequencing technology and computational biology which led to identifying
underlying causes for complex traits, utilization of X chromosome data lags behind the auto-
somes. This can be attributed to the inherent complexities of analyzing X chromosome data
and extra data processing steps needed before the analysis. The aim of this thesis was to de-
velop a computational workflow for the inclusion of X chromosome analysis and improve the
shortcomings in order to supplement the existing eQTL analysis methods. We demonstrated
that after adjustment of X chromosome dosage differences between females and males, existing
workflows can be used to uncover potential causal variants for complex traits and diseases. Us-
ing RNA-seq data from human lymphoblastoma cell lines obtained from GEUVADIS project
we performed statistical fine mapping and colocalization analysis with external databases. Re-
sults show significant associations of PLP2 gene with respiratory and cardiovascular functions.
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Kokkuvõte
X kromosoomil põhineva eQTL analüüsi arvutusliku töövoo väljatöötamine
Hoolimata edasiminekutest DNA sekveneerimise tehnoloogias ja arvutusbioloogias, mille abil
on identifitseeritud komplekssete tunnuste põhjused, on X kromosoomi data analüüs autosoomi-
dest maha jäänud. Selle põhjuseks võib tuua lisasammud X kromosoomi data töötlemisel enne
analüüsimist ning X kromosoomi data analüüsimise keerukuse. Antud töö eesmärk oli täiustada
olemasolevaid eQTL analüüsimeetodeid, arendades X kromosoomi kaasav arvutuslik töövoog
ja parandada puudusi. Me näitasime, et peale X kromosoomi doosi erinevuse korrigeerimist
meeste ja naiste vahel, on võimalik kasutada olemasolevaid meetodeid potentsiaalsete komp-
lekssete tunnuste ja haiguste põhjuslike variantide tuvastamiseks. GEUDAVIS projektist saadud
inimese lümfoblastoma rakuliini RNA-seq datat kastades sooritasime statistilise peen kaardis-
tamise ning kolokalatsiooni analüüsi väliste databaaside abil. Tulemused näitavad statistiliselt
olulisi seoseid PLP2 geeni ning respiratoorsete ja kardiovaskulatoorsete funktsioonidega.
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Introduction
Advances in molecular genetics led to the fast-paced identification of genes that are associated
with human diseases. Traditionally research focused on single gene single disease model, where
finding the gene responsible for abnormal phenotype was the goal. In fact, many well-studied
diseases are transmitted in various monogenic (Mendelian) ways. Cystic fibrosis is caused
by an autosomal recessive mutation in the CTFR gene, sickle-cell anemia is associated with an
autosomal dominant mutation in the beta hemoglobin gene and an X-linked mutation in the gene
responsible for the production of dystrophin leads to Duchenne syndrome. [1] Nevertheless,
most traits are thought to be complex. Complex phenotypes arise from the accumulation of
individually small effects of multiple genes and environmental factors. This is one of the main
drivers of variation in population but also serves as a feedback mechanism to diminish adverse
effects in the case of mutation in genes associated with the trait. [2]
The majority of the disorders arise when regulatory mechanisms can not compensate for the
change (loss) of function caused by mutations. Most prevalent diseases such as diabetes, heart
diseases, obesity, etc. are classified as complex diseases. [3] The very nature of complex traits
makes it difficult to find associated regions in the genome that would explain the phenotype. The
most resorted method for discovering these associations is Genome-Wide Association Studies
(GWAS). In spite of generating a large amount of data, GWAS has its shortcomings which I
will discuss further. Additionally, the existence of a certain variant in the genome does not
always mean it will have any observable effect on the phenotype of interest. Expression of
the variant or effect of the variant on the expression of another locus usually determines the
outcome. Hence, eQTL analysis which focuses on the variance of gene expression is often
performed after GWAS.
Despite the advances in computational biology, analyzing sex chromosomes remains chal-
lenging due to experimental constraints and the additional effort needed for data processing.
This has resulted in the omittance of sex chromosomes from GWAS and post GWAS studies.
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[4] It is crucial that we develop analysis methods that include sex chromosomes, especially the
X chromosome that has been shown to carry loci associated with many known human diseases.
This work aims to supplement existing eQTL analysis methods by developing a computational
workflow that includes X chromosome analysis and improves on inherent shortcomings such as
differences between males and females in the dataset.
The thesis is structured in the following way. Chapter 1 describes the literature on the topic
and summarizes the problem in hand. Chapter 2 discusses the methods used in the study and




First introduced in 2005, Genome-Wide Association Studies (GWAS) in which a collection of
genetic variants are tested to link genotype to the observed phenotype, has revolutionized the
study of complex disorders. [5] As the cost of genome sequencing came down exponentially,
the number of GWAS published increased rapidly. [6] Benefits that came from it include the
discovery of new drug targets, estimating disease susceptibility, and practical applications in
personalized medicine fields such as adjusting the dosage of administered drugs based on the
patient’s genotype. [7] GWAS can also find associations with low frequency and rare variants.
Predictably, the number of associations found significantly increases with the number of sam-
ples analyzed. This inevitably increases the cost associated with GWAS. As a result, most stud-
ies make use of genome-wide single nucleotide polymorphism (SNP) arrays and subsequent
statistical imputation of unobserved genotypes using the reference panel. Moreover, GWAS
only explains a fraction of the heritability of complex traits. [8] Most GWAS hits pinpoint to
noncoding regions of the genome hence making it challenging to find the causal variant, hence
the gene of interest. [9] Producing multiple association hits with a given trait further increases
the challenge of identifying the causal variant. Considering all the limitations of GWAS focus
has been shifting to post-GWAS research to further illuminate the genetic mechanism behind
the complex diseases.
1.2 eQTL
With the increased availability of transcriptomic data which catalogs the mRNA levels in dif-
ferent cell and tissue types, eQTL analysis has been proposed to be the next step after GWAS.
eQTL is defined as a locus that explains variance in expression levels of a gene. An SNP that
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has been found to be associated with a trait in GWAS has a 3 times higher chance of being
associated with gene expression, hence to be an eQTL [10]. Based on the enrichment of asso-
ciated SNPs in different tissue and cell types eQTL analysis also allows identifying the causal
cell type of the complex disease. Hu et al.. demonstrated that CD4+ T-cells are causal cell
types for rheumatoid arthritis while B-cells are related to Lupus Erythematosus [11]. Funda-
mentally, eQTL analysis bridges the gap between the genetic variation and disease by profiling
the intermediate phenotypes in the shape of SNP −→ gene expression −→ trait (Figure 1.1).
Figure 1.1: Flow from genetic variation to a trait. Variation in genetic code shows its effect
on a trait through many intermediate phenotypes. This figure summarizes the road from Single
Nucleotide Polymorphism to the hypothetical disease state.
eQTLs are classified as cis-eQTLs that act on local genes (+- 1MBP <) and trans-eQTLs that
act on distant genes. Cis-regulatory variance derives from variation in regulatory regions where
transcription factor binds while trans variation is generally the result of variation in transcription
factor itself. Research suggests that most genes are regulated by cis-eQTLs and they tend to
have larger effect sizes [12]. In the most simplistic way, eQTL analysis discovers the linear
regression equation that relates the expression to the genotype. Using the equation of
Yi = B0 +B1Xi + εi (1.1)
we can estimate a phenotype Y from the expression level X while accounting for basal expres-
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sion of B0, slope B1 and error εi (Figure 1.2).
Figure 1.2: Linear regression graph of eQTL [13]. Trait value associated with variant increases
proportionally to the number of alles of interest the individual possesses.
1.3 Genotype imputation
Although the cost of whole-genome sequencing has decreased many folds in recent years, it is
yet not feasible to sequence thousands of people for analysis. Instead, researchers use SNP ar-
rays with the size of 100000 to 1000000 variants. Considering the fact that more than 10 million
estimated genetic variants exist, a typical study only covers a small fraction of the genome. This
limited data is still helpful and can uncover many associations. A 2006 paper by Burdick et al.
suggested a method for inferring the rest of the missing data computationally [14]. Now known
as genotype imputation, this method makes use of a reference panel of haplotypes or geno-
types and allows to evaluate associations of SNPs that are not directly genotyped. The main
principle of imputations is that stretches of chromosomes are genetically linked and inherited
together. This assumption holds for related and unrelated individuals with a significant differ-
ence being the much shorter shared haplotype stretch for unrelated individuals. [15] After the
haplotype is identified by genotyped SNPs missing variants can be filled with different algorith-
mic approaches such as heuristic, expectation-maximization, or more complicated Markovian
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coalescent models. Figure 1.3 depicts the simplified representation of genotype imputation.
Figure 1.3: Genotype imputation. Graphical representation of a hypothetical imputation of
haplotypes froma reference panel
There are two main classes of genotype imputation tools. The first class includes tools
that use all observed variants to impute missing SNPs and are resource-intensive. IMPUTE
[16], MACH [17], and fastPHASE/BIMBAM [18] are examples of this class. The second more
computationally efficient software only uses markers near the imputed genotype to make a
prediction. Well-known examples include PLINK [19], TUNA [20], and BEAGLE [21]. These
tools provide remarkable accuracy of over 90 percent [15]. Whenever a variant can not be
imputed with high confidence, most of the mentioned tools provide probability scores for the
identity of the genotype. Obtained partial information can still be effectively used in association
13
analysis.
There are several use cases of genotype imputation. It increases the power of GWAS studies.
On average 10% more peaks can be obtained on loci of interest after imputation. [22] It can
also accelerate genetic fine-mapping research. After obtaining an association signal, genotype
imputation allows us to zoom in and test for association in nearby SNPs. This procedure aids
in identifying the potential causal variants. Furthermore, genotype imputation facilitates the
meta-analysis of different cohorts. When different chips are used for genotyping, imputation
can equate the set of SNPs across studies. Results then can be combined together to increase
the power of analysis by increasing the sample size. [23]
1.4 Statistical fine mapping
GWAS helps to identify a region on the genome that has the possibility of containing a causal
variant. This is only the first step and additional statistical analysis should be performed to
differentiate causal variants from the variants that are correlated with causal variants due to
proximity. Most of the SNPs on microarray chips are variants that have a large linkage dise-
quilibrium (LD) with the causal variants in their neighborhood. [24] LD can be defined as the
together inheritance of the alleles within a haplotype more than it would be suggested by ran-
dom chance. [25] Often LD patterns between SNPs are complex and it is not easy to identify
the causal SNP. Statistical fine-mapping can help us unravel the causal variants. For performing
fine mapping we need an association of region on the genome with a trait found in previous
studies and the assumption that a casual variant exists. Firstly associations are discovered using
GWAS. Hits over a threshold significance value (P-value < generally 5∗10−8) [26] are selected
and the locations of these lead SNPs are tagged for fine mapping. A sample workflow for fine
mapping is shown in the Figure 1.4 below.
Other than LD several other criteria can influence the power of fine mapping. Two main
examples are SNP density and sample size. Sample size can be increased with a costly method
of sampling more individuals or combining data from different studies at the cost of losing
statistical power. For increasing SNP density we can use genotype imputation. An important
factor while imputing genotype sit to choose an appropriate reference panel for the dataset at
hand. Expectedly, the less accurate the imputation is, the less significant associations we will
detect. [22]
Once significant SNPs are selected by fine-mapping we can proceed to decode their bi-
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Figure 1.4: Fine mapping workflow. A representation of a genotype fine-mapping workflow
which starts with GWAS analysis.
ological functions. Databases such as Gene Ontology [27] and ENCODE [28] can provide
information about the enrichment of functional annotations. Generally, annotations are catego-
rized into protein-coding and non-coding sequences. SNPs in coding regions can directly affect
the conformation of the resulting protein while non-coding variation can have an effect on gene
regulation. Non-coding annotations can be classified as, promoters, terminators, enhancers,
transcription factor binding sites, epigenetic modification sites and etc.
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1.5 X chromosome issues
Sexual dimorphism can be observed in many complex traits. Autoimmune disorders, cardio-
vascular diseases, and behavioral conditions demonstrate sex bias. Studies show that loci on the
X chromosome have a higher probability of showing expression variance based on sex when
compared to loci on autosomes. [29] Chromosome X is the 8 largest human chromosome with
a length of 156 megabase pairs and 1669 discovered genes. [30] This accounts for around 5%
total number of human genes. According to the Online Mendelian Inheritance in Man (OMIM)
database, 7% of the diseases with known mechanisms are X-linked (Figure 1.5). [31]
Although the importance of the X chromosome in deciphering complex traits is well demon-
strated by the above-mentioned facts, when it comes to analysis X chromosome is often ex-
cluded by researchers. The X chromosome has the least number of associations found in distinct
loci in published GWAS studies after the Y chromosome. [4] Given its size and the number of
genes it contains which is in turn similar to chromosome 7, it is very likely that we have yet to
discover most of the associations on the X chromosome. Authors generally report a few com-
mon reasons for the exclusion of the X chromosome. Low coverage of chromosome X in mi-
croarray assays, lower genotyping accuracy compared to autosomes, and relatively challenging
nature of analysis and interpretation of the data are some of them. Most of the new microarray
assays now include a wide overage of the X chromosome. It is true that making sense out of
the X chromosome data requires additional effort because of a higher rate of missing data, a
higher frequency of chromosomal abnormalities, and dosage difference between male and fe-
male samples. Clustering algorithms generally perform worse on the X chromosome leading
to lower accuracy scores. [4] Genotype imputation protocols for X chromosome are very sim-
ilar to autosomes. The prime source of complexity comes from the dosage difference between
males and females. Although most available imputation tools can in principle compensate for
it are generally omitted from the software. In addition, the hemizygosity of males results in a
decrease of the sample size by a quarter. [22] Combining all these reasons and the probability of
obtaining enough publishable material only using autosomal data without spending extra effort,
results in sex chromosomes lagging behind autosomes in research.
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Figure 1.5: X chromosome associated complex traits.
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2 Methods and result
We based the imputation and quality control stage of my project on the eQTL catalogue’s gen-
impute workflow developed by my supervisor Dr. Kaur Alasoo and added the ability to incor-
porate chromosome X to the workflow. [32] Figure 2.1 describes the summary of the work done
in consecutive steps.
2.1 Preparing VCF files for eQTL analysis
Generally, genomics data is stored in Variant Call Format (VCF) format. VCF is a compressed
tab-separated text file. It stores meta-information such as headers, sample IDs, and positions
on the genome. Individual identification numbers are stored on rows while columns correspond
to data such as the genotype of the individual at a given SNP. Figure 2.2 shows sample data
stored in VCF format for genomic analysis. One of the most effective ways of working with
VCF files is using BCFtools software. BCFtools is a freely available utility set that allows us to
manipulate VCF files efficiently. [33]
Before performing statistical analysis on sequencing data, quality control measures need to
be taken. For quality control steps we have used PLINK 1.9 software. Firstly we converted VCF
files to plink files. We used the “–make-bed” flag of plink. The next step involved imputing the
sex of the samples using PLINK. Following the separation of the X chromosome from the rest
of the data we excluded pseudoautosomal regions - regions that are shared between X and Y
chromosomes - from the next steps. We designated heterozygote haploid genotype to “missing”
via PLINK. At this point, we extracted the list of female samples which will be used later on
quality control steps. It is worth noting that we had to change the file names for the chromosome
X multiple times during the process to ensure compatibility with the different tools we are using.
Subsequently, we used the Genotype harmonizer command-line tool [35] to align our data with
1000 genomes project data which we used as reference. [36]
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Figure 2.1: Summary of the project workflow.
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Figure 2.2: Sample genomic data stored in VCF format. [34]
Prior to proceeding to genotype imputation, we used the Eagle2 algorithm for haplotype
phasing. [37] Haplotype phasing is the process of inferring haplotypes from given genotype
data. Afterward, we used Minimac software for imputing genotypes in our project. [38] Min-
imac is a computationally efficient variant of the MaCH algorithm. It takes a VCF file as an
input and outputs a VCF file with imputed genotypes. We used a reference panel from the 1000
Genomes project for our imputation. Following completing all the steps we used the merge
function of BCFtools to firstly merge together dosage adjusted male samples to female samples
and then X chromosome to the rest of the chromosomes. We filtered variants with missingness
over 5% and minor allele frequency of less than 1 percent. We removed the coordinates of vari-
ants that passed quality control and used it to filer our data file to only contain quality control
passed variants using BCFtools again.
I used VCF files from the GEUVADIS study [39] for preparing GEUVADIS data for eQTL
analysis I first separated it into chromosomes. I used “bcftools view -r chr ” to split files. Since
genomics files are very big in size, this step is necessary to avoid memory constraints and allow
parallelization of the workflow. Despite having genotype data GEUVADIS files lacked dosage
information for samples. We needed dosage information since qtlmap workflow used on the
next steps depends on it to determine the number of alternative alleles in eQTL analysis. A given
person can have a dosage of 0 if they lack the allele of interest, 1 if they are heterozygotes, and 2
if they are homozygotes. In spite of being very useful in manipulating VCF files, BCFtools does
not have a straightforward way to calculate dosage based on genotype and add a dosage field
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to files. I developed a script to tackle this problem and infer dosage from the genotype (Figure
2.3). This script altered the column named “GT” (genotype) to contain dosage information in
the format of “GT:DS”. I used this script on all autosomes subsequently.
Figure 2.3: Dosage from genotypes python script. This script calculates dosage from genotypes
and add it to the GT column converting it to GT:DS format. The script is only applicable for
autosomes and X chromosomes of females.
Before proceeding to the X chromosome I filtered VCF files based on sex to 2 different
files. Although there are multiple ways that dosage difference between male and female can
be addressed in our project we decided to multiply the dosage of male samples by a factor
of 2. Having double the number of X chromsomescompared to males does not translate into
having double the gene expression amount in females. During embryonic development, by
the process called X inactivation, females transcriptionally disable one of their X chromsomes.
Each copy is silenced in roughly the amount of cells. Subsequently females have mosaic of
cells with different copy of X chromosome inactivated. This results in having the same dosage
as males when it comes to loci found on X chromsome. Cite here Doubling male dosage in
our workflow makes sure that the dosage balance is maintained throughout the analysis. [40]
I developed a python script that can be used as a command-line tool to take a VCF file as an
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input, manipulate the GT column which contains genotype information. The script does not
alter genotype information while multiplying male dosage coefficients by 2. Similar to the
autosomes it then adds a dosage field to the genotype column creating a column formatted as
“GT:DS”. Afterward, it outputs a VCF file with altered dosage information. Figure 2.4 shows
the script I used to multiply male dosages.
Figure 2.4: Dosage Multiplier python script. This script calculates dosage from genotypes
and add it to the GT column converting it to GT:DS format. The script is only applicable for
autosomes and X chromosomes of males.
Following the completion of dosage adjustment, I added headers back to the VCF files using
“reheader” flag of BCFtools. I proceeded to reorder and index X chromosome files for males
and females using “index” flag of BCFtools. I merged these files together as one before pro-
ceeding to create a single dosage adjusted file that included all chromosomes using the “merge”
function.
2.2 QTLmap analysis
I submitted processed and QTLmap ready VCF files to Dr. Alasoo for eQTL fine-mapping
analysis with sex as a covariate. I received a file that contains genetic variants that are likely
to causally regulate gene expression. After filtering results that I received from him for the X
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chromosome there are remaining 1884 eQTLs. They shared between 91 fine mapped credible
sets. T perform colocalization analysis with complex traits and diseases I used two different
GWAS datasets. FinnGen data can be accessed at https://r4.finngen.fi/top hits and GWAS cat-
alog data at https://www.ebi.ac.uk/gwas/docs/file-downloads. FinnGen dataset contained 668
associations on the X chromosome and the GWAS catalog had 1255 associations. The result
of the colocalization analysts gave us 1 colocalization with FinnGen data and 7 with GWAS
catalog. They are summarized in Table 2.1.
To further validate our eQTL signals we compared PLP2 hit to OpenTargets Genetic portal
[41]. We compared our results to Phenome-wide association study of variant number 49171812
which take an SNP as an input and test its association against a large number of phenotypic
variants. As seen from the PheWAS of PLP2 in Figure 2.5, the signal has been confirmed with
multiple previous studies and is significantly associated with respiratory functions such as vital
capacity, forced expiratory volume, and cardiovascular traits such as platelet distribution width.
Table 2.1: Colocalization of GEUVADIS eQTLS with FinnGen database and GWAS catalog.
















distribution width 9.000000e-10 PLP2 0.500153
49187155 mean platelet volume 4.000000e-12 PLP2 0.500153
55528377
self reported
educational attainment 1.000000e-09 KLF8 0.001232
55552777
mean corpuscular
volume 3.000000e-08 KLF8 0.000281
119433739 osteitis deformans 1.000000e-07 SLC25A43 0.043446
155491696
factor VIII
measurement 3.000000e-09 TMLHE 0.001712
53406445 E4 OBESITY HYPER 8.818000e-08 HSD17B10 0.039949
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Figure 2.5: PLP2 PheWAS. Phenome-wide association study of variant number 49171812. Tri-
angles over the red line (p-value < 5%) represent significant associations
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3 Discussion and conclusions
With the advance in the inclusion of more and more X chromosome SNPs in microarrays, we
have access to large amounts of under-utilized data. By developing a robust genotype impu-
tation workflow for the X chromosome we can take advantage of existing pipelines built for
autosomes to analyze the X chromosome as well. In this project, we started to build this work-
flow and made significant advances towards its completion.
The single most important hurdle in utilizing X chromosome data is dosage dissimilarity
between males and females. Existing software such as BCFtools does not provide a method
to add and manipulate dosage data to VCF files. I have developed command-line tools to add
dosage information to datasets while multiplying male dosage by two on the X chromosome to
compensate for their heterozygosity. I used GEUVADIS data set for demonstrating the ability
of the developed pipeline. The resulting dataset was. fully compatible with qtlmap workflow
which is designed to work with autosomes.
After statistical fine-mapping, I demonstrated overlap between our eQTLs and two major
databases in FinnGen and GWAS catalog. In total, we achieved 7 overlapping hits. We fur-
ther validated the signal by cross-checking with the OpenTarget platform which summarises
previous studies. Discovered associations were related to vital traits such as respiratory and
cardiovascular functions demonstrating the potentially very useful information waiting to be
discovered in underused X chromosome data.
It is worth noting that GEUVADIS data was collected just from human lymphoblastoid
cells. [39] By utilizing different tissues and cell lines in eQTL catalogue [32] analysis can be
expanded. It is likely that this will result in more significant associations discovered which then
can be verified in laboratory settings. By identifying causal variants and decreasing the number
of potential targets for drugs and therapies, computational workflows give an opportunity to
focus research and funds to candidates with more likelihood of success
Theoretically, all aforementioned steps can be performed manually one after another. How-
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ever, this would take an immense amount of time and organization. It is very easy to make
a mistake while dealing with many similar file names and different formats. This kind of ap-
proach would also take a lot of time since you have to run every single step one by one after each
other. For reproducibility of the research and running pipelines in parallel in high-performance
computing clusters (HPC), we used Nextflow workflow manager. [42] We integrated our scripts
into one modular pipeline. Not only it allows parts of our project to be used separately and
modified to fit the needs of researchers but it also makes our project very easily reproducible
and faster to run. This step was not fully completed due to time constraints and further effort is
needed to integrate pipelines within nextflow environment.
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of genome-wide association studies”, Nature Reviews Genetics, vol. 20, no. 8, pp. 467–
484, 2019.
[8] T. A. Manolio, F. S. Collins, N. J. Cox, D. B. Goldstein, L. A. Hindorff, D. J. Hunter,
M. I. McCarthy, E. M. Ramos, L. R. Cardon, A. Chakravarti, et al., “Finding the missing
heritability of complex diseases”, Nature, vol. 461, no. 7265, pp. 747–753, 2009.
28
[9] A. Mahajan, J. Wessel, S. M. Willems, W. Zhao, N. R. Robertson, A. Y. Chu, W. Gan,
H. Kitajima, D. Taliun, N. W. Rayner, et al., “Refining the accuracy of validated target
identification through coding variant fine-mapping in type 2 diabetes”, Nature genetics,
vol. 50, no. 4, pp. 559–571, 2018.
[10] D. L. Nicolae, E. Gamazon, W. Zhang, S. Duan, M. E. Dolan, and N. J. Cox, “Trait-
associated snps are more likely to be eqtls: Annotation to enhance discovery from gwas”,
PLoS Genet, vol. 6, no. 4, e1000888, 2010.
[11] Y. Liu, X. Liu, Z. Zheng, T. Ma, Y. Liu, H. Long, H. Cheng, M. Fang, J. Gong, X.
Li, et al., “Genome-wide analysis of expression qtl (eqtl) and allele-specific expression
(ase) in pig muscle identifies candidate genes for meat quality traits”, Genetics Selection
Evolution, vol. 52, no. 1, pp. 1–11, 2020.
[12] N. Shan, Z. Wang, and L. Hou, “Identification of trans-eqtls using mediation analysis
with multiple mediators”, BMC bioinformatics, vol. 20, no. 3, pp. 87–97, 2019.
[13] M. Kellis, Lecture 15 – Mediation, eQTLs population genetics, history, Machine Learn-
ing in Genomics lecture slides, MIT, Fall 2020.
[14] J. T. Burdick, W.-M. Chen, G. R. Abecasis, and V. G. Cheung, “In silico method for
inferring genotypes in pedigrees”, Nature genetics, vol. 38, no. 9, pp. 1002–1004, 2006.
[15] Y. Li, C. Willer, S. Sanna, and G. Abecasis, “Genotype imputation”, Annual review of
genomics and human genetics, vol. 10, pp. 387–406, 2009.
[16] J. Marchini, B. Howie, S. Myers, G. McVean, and P. Donnelly, “A new multipoint method
for genome-wide association studies by imputation of genotypes”, Nature genetics, vol. 39,
no. 7, pp. 906–913, 2007.
[17] Y. Li, C. J. Willer, J. Ding, P. Scheet, and G. R. Abecasis, “Mach: Using sequence and
genotype data to estimate haplotypes and unobserved genotypes”, Genetic epidemiology,
vol. 34, no. 8, pp. 816–834, 2010.
[18] D. J. Schaid, C. M. Rowland, D. E. Tines, R. M. Jacobson, and G. A. Poland, “Score
tests for association between traits and haplotypes when linkage phase is ambiguous”,
The American Journal of Human Genetics, vol. 70, no. 2, pp. 425–434, 2002.
[19] C. C. Chang, C. C. Chow, L. C. Tellier, S. Vattikuti, S. M. Purcell, and J. J. Lee, “Second-
generation plink: Rising to the challenge of larger and richer datasets”, Gigascience,
vol. 4, no. 1, s13742–015, 2015.
29
[20] D. L. Nicolae, “Testing untyped alleles (tuna)—applications to genome-wide association
studies”, Genetic Epidemiology: The Official Publication of the International Genetic
Epidemiology Society, vol. 30, no. 8, pp. 718–727, 2006.
[21] S. R. Browning, “Multilocus association mapping using variable-length markov chains”,
The American Journal of Human Genetics, vol. 78, no. 6, pp. 903–913, 2006.
[22] J. Marchini and B. Howie, “Genotype imputation for genome-wide association studies”,
Nature Reviews Genetics, vol. 11, no. 7, pp. 499–511, 2010.
[23] E. Zeggini, L. J. Scott, R. Saxena, B. F. Voight, J. L. Marchini, T. Hu, P. I. de Bakker,
G. R. Abecasis, P. Almgren, G. Andersen, et al., “Meta-analysis of genome-wide asso-
ciation data and large-scale replication identifies additional susceptibility loci for type 2
diabetes”, Nature genetics, vol. 40, no. 5, pp. 638–645, 2008.
[24] D. MacArthur, T. Manolio, D. Dimmock, H. Rehm, J. Shendure, G. Abecasis, D. Adams,
R. Altman, S. Antonarakis, E. Ashley, et al., “Guidelines for investigating causality of
sequence variants in human disease”, Nature, vol. 508, no. 7497, pp. 469–476, 2014.
[25] D. J. Schaid, W. Chen, and N. B. Larson, “From genome-wide associations to candidate
causal variants by statistical fine-mapping”, Nature Reviews Genetics, vol. 19, no. 8,
pp. 491–504, 2018.
[26] T. Zeller, S. Blankenberg, and P. Diemert, “Genomewide association studies in cardio-
vascular disease—an update 2011”, Clinical chemistry, vol. 58, no. 1, pp. 92–103, 2012.
[27] G. O. Consortium, “The gene ontology: Enhancements for 2011”, Nucleic acids research,
vol. 40, no. D1, pp. D559–D564, 2012.
[28] Y. Zhao, E. Schaafsma, and C. Cheng, “Applications of encode data to systematic analy-
ses via data integration”, Current opinion in systems biology, vol. 11, pp. 57–64, 2018.
[29] K. R. Kukurba, P. Parsana, B. Balliu, K. S. Smith, Z. Zappala, D. A. Knowles, M.-J. Favé,
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